CliffBio
biologic

Mvasi

bevacizumab-awwb

Loss of exclusivity—loss of exclusivity
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameMvasi
Active ingredientbevacizumab-awwb
Strength400MG/16ML (25MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalSeptember 2017
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

Mvasi patent cliff — loss of exclusivity — | CliffBio